Drug Profile
Research programme: respiration disorders therapeutics - AstraZeneca/Pieris Pharmaceuticals
Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Pieris Pharmaceuticals
- Developer AstraZeneca; Pieris Pharmaceuticals
- Class Lipocalins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiration disorders
Most Recent Events
- 18 Jul 2023 Discontinued for Respiration disorders in United Kingdom (Inhalation)
- 18 Jul 2023 Discontinued for Respiration disorders in USA (Inhalation)
- 04 Apr 2023 Research programme: respiration disorders therapeutics - AstraZeneca/Pieris Pharmaceuticals is still in research phase for Respiration disorders in United Kingdom and USA